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Abstract 
Purpose: To evaluate the influence of tumor motion on dose delivery in highly modulated 
stereotactic body radiotherapy (SBRT) of lung cancer using volumetric modulated arc therapy 
(VMAT). 
Methods: 4D-CT imaging data of the quasar respiratory phantom were acquired, using a 
GE Lightspeed 16-slice CT scanner, while the phantom reproduced patient specific respiratory 
traces. Flattening filter-free (FFF) dual-arc VMAT treatment plans were created on the acquired 
images in Pinnacle3 treatment planning system.  Each plan was generated with varying levels of 
complexity characterized by the modulation complexity score. Static and dynamic measurements 
were delivered to GafChromic EBT3 film inside the respiratory phantom using an Elekta Versa 
HD linear accelerator. The treatment prescription was 10 Gy per fraction for 5 fractions. 
Comparisons of the planned and delivered dose distribution were performed using Radiological 
Imaging Technology (RIT) software. 
Results: For the motion amplitudes and periods studied, the interplay effect is 
insignificant to the GTV coverage. The mean dose deviations between the planned and delivered 
dose distribution never went below -2.00% and a minimum dose difference of -5.05% was 
observed for a single fraction. However for amplitude of 2 cm, the dose error could be as large as 
20.00% near the edges of the PTV at increased levels of complexity. Additionally, the 
modulation complexity score showed an ability to provide information related to dose delivery. 
A correlation value (R) of 0.65 was observed between the complexity score and the gamma 
passing rate for GTV coverage.  
xvii 
Conclusions: As expected, respiratory motion effects are most evident for large amplitude 
respirations, complex fields, and small field margins. However, under all tested conditions target 




1.1 Background and Significance 
1.1.1 Lung Cancer 
Lung cancer is the second most diagnosed cancer in men and women, but the leading 
cause of cancer death in both (American Lung Association, 2015). Lung cancer accounts for 
approximately 37% of all cancer mortality and the stage of the disease at diagnosis is heavily 
related to outcome, as shown in Figure 1. When an individual is diagnosed after the cancer has 
metastasized, the expected 5-year survival is approximately 4%. In contrast, when an individual 
is diagnosed in the localized stage of the disease the expected 5-year survival is approximately 
54%. Figure 1 likewise displays the relative number of individuals diagnosed at the 
corresponding stages. Although the number of individuals with a localized diagnosis represents a 
small percentage of the total number of diagnosed lung cancers, this number is expected to 
increase with the use of computed tomography (CT) scans as a lung cancer screening tool for 
high-risk individuals. 
For localized lung cancers, surgical resection is currently considered the standard of care. 
However, many patients diagnosed with lung cancer are elderly or have health deficits that make 
them unsuitable candidates for surgery. Radiation therapy is the preferred treatment option for 
patients unwilling or unsuitable for surgery (National Comprehensive Cancer Network, 2015). 
Radiation therapy is the use of ionizing radiation to destroy cancerous cells. Radiation 
therapy can be administered internally or externally. Internal radiation therapy, or brachytherapy, 
involves the administration of radiation from within the patient’s body. In contrast, external 
radiation therapy, most commonly delivered with a medical electron accelerator, involves the  
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administration of radiation beams to the patient and is the primary method of lung cancer 
treatment. 
1.1.2 Stereotactic Body Radiation Therapy 
Stereotactic body radiation therapy (SBRT) is one specialized form of external beam 
radiation therapy treatment that utilizes hypofractionated radiation doses delivered in a limited 
number of fractions. The hypofractionated doses in SBRT are believed to not only result in 
clonogenic cell death but also in vascular damage, stromal damage and immune system 
activation, all of which help improve local control. Stereotactic treatments are also characterized 
by small treatment volumes and sharp dose fall off into the surrounding healthy tissue.  
SBRT’s hypofractionated doses have shown to be very effective at treating localized lung 
cancer (Bezjak et al., 2014). The small treatment volumes and sharp dose fall-off limit the 
amount of healthy lung tissue treated; which is desirable considering that mean lung dose 
correlates with lung complications (Yorke et al., 1996). Though effective, SBRT necessitates 
careful targeting of the tumor volume. Therefore, the use of image guidance, immobilization and 
motion management is required. 
Figure 1: Percentage of lung cancer patients diagnosed at the localized, regional and distant 
stage of the disease with corresponding 5-year survival. (American Lung Association, 
2015) 
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Image guidance is the use of imaging before, during, or after a radiotherapy course for 
the purpose of improving the precision and accuracy of each treatment delivery (RadiologyInfo, 
2014). Most modern linear accelerators utilize onboard kilo-voltage cone beam computed 
tomography (kV-CBCT) imaging systems to acquire volumetric images before each treatment 
(Figure 2). 
These systems allow for verification of location, shapes, and volumes of treatment 
targets, organs at risk, and surrounding normal tissues, leading to a reduction in daily setup 
errors. Image guidance is crucial for treating tumors in areas of the body that are prone to 
movement or located near critical organs and tissues. When considering SBRT treatments, image 
guidance is particularly important in that it provides quality setup prior to each treatment.  
kV Detector 
    Panel
kV X-Ray 
 Tube 
MV Detector   
     Panel
Linac Head 
Figure 2: Mary Bird Perkins Cancer Center Elekta Versa HD linear accelerator with 
onboard MV-CBCT and orthogonal kV-CBCT imaging. 
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Immobilization helps establish and maintain the patient in a fixed, well-defined position 
to minimize daily setup differences (inter-fraction motion) and patient motion during treatment 
(intra-fraction motion) over a radiotherapy course (RadiologyInfo, 2014). Immobilization must 
be considered in SBRT since large fractional doses considerably increase treatment time, which 
increase the likelihood of patient motion. Common immobilization devices to reduce voluntary 
patient motion for stereotactic procedures include stereotactic body frames, stereotactic head 
frames, thermoplastic shells, and bite blocks, among others. Unfortunately, respiratory motion is 
a major component of patient intra-fraction motion and is particularly difficult to manage. As a 
result, additional motion management techniques are needed to limit or account for patient 
respiratory motion.   
Respiratory motion can complicate the radiation therapy imaging, treatment planning and 
delivery processes by introducing a temporal component which is not customarily accounted for 
in radiotherapy. For example, respiratory motion can affect the location of the tumor, make it 
difficult to detect microscopic disease, and distort the target volume causing incorrect positional 
and volumetric information during the CT image acquisition process, as seen in Figure 3. 
Distorted and incorrect imaging data becomes problematic when trying to determine and 
delineate treatment planning margins during the planning process, typically resulting in the use 
of larger margins around the tumor, which consequently results in more normal tissue being 
treated. Respiratory motions can also cause averaging or blurring of the dose distribution over 
the path of the motion during radiation delivery; thus giving unintended deviations between the 
planned and delivered dose distribution. Hence, respiratory motion is very important and requires 
careful assessment. 
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1.1.3 Four-Dimensional Computed Tomography 
Four-dimensional computed tomography (4D-CT) scan involves the acquisition of 
standard CT data sets at various phases throughout the breathing cycle. This method has been 
used to address the issues presented by respiratory motion in the imaging acquisition process. In 
4D-CT acquisition, a cine CT is acquired by obtaining a continuous series of timed images over 
an entire breathing cycle at each fixed couched position, as the couch is indexed throughout the 
entire field of view (FOV).  
During cine image-acquisition, respiratory surrogates are used to generate a respiratory 
trace. The respiratory trace is used to tag each acquired cine image with a respiratory phase 
value. Both, the cine data and respiratory trace are sent to binning software where the images are 
sorted into bins based on phase value. Each bin, representing a 3D-CT data set, is part of the 4D-
CT data set that together represents the entire breathing cycle. 
Figure 3: Example of motion artifacts from scanning a moving sphere. Top row: Artifacts of 
the moving sphere when scanned with a helical free breathing-CT. Bottom row: true 
geometry of the sphere. (Rietzel et al., 2005) 
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The 4D-CT binning software also has the ability to create unique intensity projection 
data sets. The maximum intensity projection (MIP) data set is particularly important in that it 
shows all possible positions of the tumor throughout the respiratory cycle. This data set is 
generated by displaying the greatest pixel value (highest attenuation) across all phases, Figure 4. 
Currently, the MIP data set is used in treatment planning to delineate a motion encompassing 
region of interest (ROI) that fully encompasses the extent of the tumor’s motion. 
1.1.4 Volumetric Modulated Arc Therapy (VMAT)   
Volumetric Modulated Arc Therapy (VMAT) is an advanced radiation delivery technique 
that delivers fluence modulated radiation fields while the gantry of a linear accelerator is rotating 
through one or more arcs.  During arc delivery, near continuous variations of gantry rotation 
speed, dose rate and multi leaf collimator (MLC) position modulate the beam’s fluence in an 
effort to deliver a conformal dose distribution. The MLCs are leaves made of tungsten material 
located in the head of a linear accelerator and are the driving force behind conformal dose 
distributions and fluence modulated fields in VMAT (see Figure 5). 
Figure 4: Positional differences between the tumor positions on the free-breathing (A) and the 
MIP (B) data sets. Contours represent the ITV (red) and PTV (orange). (Glide-Hurst et 
al., 2014) 
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VMAT has several advantages over other fluence modulated techniques. VMAT has the 
ability to deliver radiation therapy treatments in shorter periods of time and with increased 
monitor unit efficiency, while maintaining comparable or more conformal target coverage and 
critical structure sparing than Intensity Modulated Radiation Therapy (IMRT) (Li et al., 2013; 
Ong et al., 2011; Ramsey et al., 2001; Rao et al., 2012). As a result, VMAT treatments are more 
tolerable for the patient and provide additional time for image guidance, which are important 
considerations when treating with SBRT.  
1.2 Research Motivation 
When using fluence modulated techniques there are concerns of interplay between 
moving tumors and dynamically changing parameters, most notably MLC motion. Interplay is 
the result of treatment planning dose calculations on stationary CT data sets. A treatment 
volume, assumed to be stationary in treatment planning, is modulated by segments of time-
dependent changes in MLC and gantry positions. During delivery, the displacement of this 
Figure 5: MLC leaves from both leaf banks forming desired shape (looking into gantry head). 
(Garcia-Garduno et al. 2008) 
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volume, relative to the moving MLC leaves, results in deviations between the planned and 
delivered dose distributions. 
Previous investigations of interplay have been reported for lung cases using conventional 
fractionation schemes (e.g. 30 fractions at 2 Gy per fraction). For sliding widow and step-and-
shoot IMRT, Jiang et al., (2003) used a motor driven platform to simulate one-dimensional 
sinusoidal movements. Solid water was placed on top this platform with a Farmer chamber 
inside and clinical lung cancer treatment plans were delivered. This study observed that interplay 
effects could result in an 18% dose variation for a single fraction.  
Seco et al., (2007) used an in-house made motor driven platform to simulate one-
dimensional sinusoidal breathing motion. An ionization chamber and Kodak X-Omat films were 
used to measure the dose in the moving phantom. Interplay’s dose variations were observed to be 
greatest for IMRT beam segments with low monitor units (MU).  
Chui et al., (2003) developed a computational algorithm that calculates the effects of 
respiration-induced organ motion on delivered dose for sliding widow and step-and-shoot IMRT. 
This study reported that the effects of organ motion broadened the penumbra and degraded the 
coverage of the planning target volume for lung treatments.  
For conventionally fractionated VMAT, Court et al., (2008) exported static dose 
distributions were to written software, which recalculated the dose distribution being delivered to 
a moving target. Moreover, an experimental dynamic phantom, on which an ion chamber array 
was mounted, was programmed to simulate various motions as treatments plans delivered. The 
results indicated that dose variations were largest for small MLC separation and fast moving 
MLCs. Also, it was observed that dose variations are largest for complicated MLC sequences, 
large amplitudes and single arcs. 
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 However, under clinical conditions, all studies above concluded that the use of multiple 
beams per fraction and several fractions per treatment course causes the interplay effect to be 
averaged out and dosimetrically insignificant for conventional fractionation schemes (Chui et al., 
2003; Court et al., 2010.; Jiang et al., 2003; Seco et al., 2007).  
The use of fewer treatment fractions and increased dose per fraction could result in very 
different statistics of interplay. Kang et al., (2010) recalculated the dose distributions of nine 
clinical hypofractionated IMRT lung cancer treatments plans, simulating one-dimensional tumor 
motion, to assess perturbations in delivered doses from respiratory motion. This study indicated 
that variations in target coverage had minimal dependence on respiratory period or initial phase. 
Dose variations were more dependent on amplitude, degree of modulation and field margin; all 
of which led to significant changes in target coverage for highly modulated fields.  
Stambaugh et al., (2013) used a 4D dose reconstruction method on SBRT VMAT plans 
by applying perturbations to the treatment planning system calculated static 3D dose. Their 
results showed that intra-fraction interplay is minimal for clinical conditions (<0.2%). It is also 
small (0.9% average, 2.2% maximum) when the target excursion is increased to 2–3 cm. 
Additionally, when comparing single and multiple fractionations, interplay effects are reduced as 
you increase the number of fractions.  
Li et al., (2013) considered interplay effect in flattening filter-free dual-arc VMAT SBRT 
plans. Their process entailed a 3D dose calculation from the Eclipse treatment planning system 
being processed by in-house software to generate a 4D VMAT plan. The 4D VMAT plan is the 
original static 3D dose distribution where radiation is delivered only during the respiratory phase 
or phases that receives dose from a corresponding control point. Their results showed that the 
coverage difference between the 3D and 4D dose calculations were either unchanged or slightly 
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increased up to 1.2%, and the variations of their minimum doses were less than 3.2% for the 6 
patients studied. However, there were significant changes in the PTV coverage and, therefore, it 
was concluded that with significant margin the interplay effect would be insignificant. 
 Rao et al., (2011) studied the interplay effect in VMAT SBRT lung treatments. This 
simulation study conducted a planning based investigation on 4D-CT phase sets. 3D dose 
calculations were performed on the end-of-exhale phase set and compared to its recalculated 
dose distribution distributed on all phase sets (i.e. 4D dose calculation) by copying the 3D phase 
set planning parameters. This study observed negligible interplay effects for all plans studied. 
However, one stated weakness of their study was the minimal use of modulation in their 
treatment plans. This was indicated by majority of their aperture shapes conforming to the PTV 
and few aperture shapes containing MLC leaves that block part of the target. 
SBRT treatments have been implemented at Mary Bird Perkins Cancer Center (MBPCC) 
with VMAT since 2009. Over the course of the program, the treatment team has observed some 
circumstances of high plan modulation; such as lung tumors that are in close proximity to critical 
structures where significant dose sparing is required. Therefore, the goal of this study is to assess 
VMAT SBRT dose delivery under increased levels of modulation. Evaluation of target coverage 
was used to gage interplay effects on the delivered dose distributions in effort to evaluate its 
clinical importance. Additionally, correlation of target coverage to a plan-based modulation 
metric was used to provide an indication of potentially risky plans. 
1.3 Hypothesis and Specific Aims 
The hypothesis of this work is that treatment plan modulation will correlate (R > 0.60) 
with changes in target coverage between planned and delivered dose distributions. The three 
specific aims that have been formulated to address the hypothesis of this work are:  
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 Aim 1: Generate Flattening Filter Free (FFF) -VMAT treatment plans with a range of  
  Modulation Complexity Scores (MCS). 
 Aim 2: Measure dose distributions for VMAT treatment plans and evaluate   
  interplay’s impact on the target’s delivered dose distribution. 



















Methods and Materials 
2.1 Aim 1 
In this aim, a respiratory motion phantom was imaged while simulating patient specific 
respiratory traces. Subsequently, treatment plans were generated using the acquired images with 
varying degrees of complexity characterized by a treatment plan complexity metric.  
2.1.1 Respiratory Phantom 
In this study, a dynamic phantom (Quasar Respiratory Phantom, Modus Medical 
Devices, Ontario, Canada) was used as a surrogate for patient geometry. The phantom is 
composed of an acrylic body and an electric drive unit designed to simulate one-dimensional 
internal lung motion with various cylindrical “lung” inserts that move in the longitudinal 
direction while simultaneously simulating one-dimensional external chest motion with a platform 
that moves in the anterior-posterior direction. The phantom’s acrylic body, internal and external 
motion features, and array of cylindrical inserts makes the device suitable for mimicking a 
breathing patient. This device, shown in Figure 6, was used throughout the imaging, planning 
and treatment process. 
In this study, the cedar lung tumor insert was used. The insert is composed of cedar 
wood and contains an offset, 3 cm diameter, plastic sphere to be used as lung and tumor 
surrogates, respectively. Cedar and plastic are typically used as surrogates for lung and tumor, 
respectively, due to their similar properties. The cedar CT numbers and densities range from 
290-400 and 0.25-0.32 g/cm3 as compared to 140-300 and 0.15-0.33 g/cm3 for lung. The CT 
number and density of the plastic sphere are 950 and 0.98 g/cm3 compared to 1000 and 1.02 
g/cm3 for patient tumors (Yorke et al., 1996). This insert, inside the phantom’s acrylic body, 
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provides the desired imaging conditions of an actual lung tumor patient. Figure 7 shows the 
cylindrical insert which splits in half for film dosimetry.  
Figure 6: Quasar respiratory motion phantom  
Platform 
Insert 
            Figure 7: Cedar lung tumor insert (left) and CT scan of cedar lung tumor insert (right). 
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2.1.2 Respiratory Motion Models 
 The control software for the phantom supports import of 1D respiratory traces that can 
be reproduced by the phantom. Using this feature, three anonymized patient-specific breathing 
traces acquired with the external tracking system (Varian Real-Time Positioning (RPM), Varian 
Medical Systems, Palo Alto, CA) used at MBPCC were attained. Two traces were selected 
where the amplitude and period of the respiratory cycles where consistent, see Figure 8-9. 
Additionally, one irregular trace was selected where the amplitude and period of the respiratory 
cycles varied, see Figure 10. The provided software utilizes a waveform editor that allows the 
user to filter, compress, stretch, and scale the amplitude of a given waveform. The software’s 
wave editor was used to set each waveform at fixed amplitudes of 1 and 2 cm, for a total of 6 
traces. Amplitudes of 1 and 2 cm were chosen, because respiratory amplitudes over 2 cm are 
relatively uncommon. This software and phantom have demonstrated the ability to reproduce 
traces to sub-millimeter accuracy (Modus QA, 2016). 
 
  Figure 8: Patient specific breathing trace one (PS1) at 2 cm amplitude. 
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2.1.3 Treatment Planning Image Acquisition  
Currently, MBPCC employs a motion encompassing imaging technique for managing 
intra-fraction respiratory motion during treatment planning and delivery of lung SBRT. Again, 
this technique involves creating a region of interest (ROI) that encompasses the target and its 
envelope of motion. To reproduce this, images of the phantom were acquired with a General 
  Figure 9: Patient specific breathing trace two (PS2) at 2 cm amplitude. 
  Figure 10: Irregular patient specific breathing trace at 2 cm amplitude. 
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Electric Lightspeed multi-slice CT scanner (General Electric Company, Waukesha, WI) using 
MBPCC’s standard clinical 4-Dimensional Computed Tomography (4D-CT) gating protocol. 
The parameters and values for the 4D-CT gating protocol are shown in Table 1. 
Table 1: MBPCC 4D-CT Gating Protocol 
Parameter Value 
Slice Thickness 2.5 mm 
Matrix Size 512 x 512 
mAs 400 
Field of View 30 cm 
kVp 120 
Cine Duration (variable) 
  
 The MBPCC 4D-CT protocol consists of taking an initial scout scan, a free-breathing 
(FB) CT scan and then a cine scan. During cine image-acquisition, Varian’s Real-time Position 
Management (RPM) system, which consists of an infrared  (IR)  tracking  camera  and  a  
reflective  marker  box  (Figure  11),  monitors  the  external chest  motion  of  the  phantom and 
generates a breathing trace.  
 
 Once acquired, the cine volumetric data and the RPM breathing trace were sent to the 
Advantage 4D-CT v1.6 binning software (GE Healthcare, Buckinghamshire, England) and a 4D-
CT data set generated. Additionally, the Advantage software was used to create a MIP data set.  
Figure 11: The Varian RPM system 4D-CT infrared camera (left) and the Varian RPM system 
reflective marker box (right). 
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2.1.4 Pinnacle3 Treatment Planning 
After imaging the FB and MIP CT data sets, Figure 12, were exported to a treatment 
planning system (TPS) (Pinnacle3, Fitchburg, Wisconsin, U.S.). The data sets were fused and the 
MIP data set was used to contour the ITV on the FB-CT data set. A uniform margin of 0.5 mm 
was added to the ITV to form the PTV. 
Flattening filter free (FFF) VMAT plans were created according to the Radiation Therapy 
Oncology Group (RTOG) 0813 and MBPCC clinical protocols on the FB-CT data sets. Several 
protocol requirements are shown in Table 2. Each FFF-VMAT plan consisted of two full 360° 
treatment arcs at 6 megavoltage (MV) photon beam energy. The collimator angle was set to 45° 
and the coach angle was 0°. VMAT plans were generated using Pinnacle3 SmartArc inverse 
planning module (Bzdusek et al., 2009). Inverse planning allows the optimization algorithm to 
determine the best method of accurately irradiating the target volume while minimizing dose to 
surrounding critical structures. All plans were optimized using a 4° control points spacing and a 
0.46 cm/degree leaf motion constraint. 
The PTV prescription was set to 1000 cGy per fraction for 5 fractions and the dose was 
calculated on a dose grid of 3x3x3 mm3. This dose fractionation scheme was selected as it is 
Figure 12: Coronal slice of free breathing-CT data set and MIP CT data set in Pinnacle
3
 
treatment planning system. 
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allowed by the RTOG 0813 protocol, the current standard at MBPCC for most cases, and 
common in the literature (Li et al., 2013; Ong et al., 2011; Ramsey et al., 2001; Rao et al., 
2012). 
Table 2: RTOG 0813 Protocol Requirements 
Normalization ≥60% and ≤90% 
PTV Coverage Prescription isodose should cover 95% of PTV 
High Dose Spillage Any dose >105% should occur in PTV 
Low Dose Spillage Dose falloff must be rapid 
Plans were created at varying degrees of complexity characterized by the modulation 
complexity score (see Section 2.1.5). This was achieved by contouring approximating regions of 
interest to represent normal anatomy. The insert inside the phantom represents a left lung tumor. 
Therefore, contours representing right lung, spinal cord, left ribs, and esophagus were delineated. 
Additionally, a region of interest (ROI) was contoured inside the ITV and PTV volume adjacent 
to the GTV, per RTOG protocol, to generate modulation in the more complex cases see, Figure 
13. The right lung, spinal cord, left ribs, and esophagus were sequentially added to increase plan
modulation. A contour was added and then the initial dose objective value was set according to 
the RTOG critical organ dose-volume limit with an objective weight of one. The contour’s dose 
objective value was progressively reduced until an objective value of 0.01 was reached. Then, 
the next contour would be delineated until the final desired modulation complexity score was 
reached. Once the desired modulation complexity score was achieved, analysis of dose-volume 
metrics, for agreement within protocol requirements, was performed. The plans and images were 
then exported from Pinnacle3 and imported into MOSAIQ Record and Verify System (Elekta 




2.1.5 Modulation Complexity Score 
The modulation complexity score (MCS) was utilized to quantify the MLC modulation of 
each plan. MCS was proposed by McNiven et al., (2012) for step-and-shoot IMRT and then 
adopted for VMAT as reported by Masi et al., (2013). The MCS has a fixed range from 0-1, with 
lower scores indicating increased modulation. MCS is calculated based on three characteristics 
of each segment: area, weight and number of monitor units. 
 Segment shape is quantified using the leaf sequence variability (LSV) parameter. LSV is 
defined as the variability in segment shapes of each field. The segment shape is based on the 
difference in leaf position between adjacent MLC leaves for each leaf bank excluding those 
positioned under the jaws. The maximum distance between positions for a leaf bank is defined as max ∈ min ∈  
The LSV is then calculated as follows: 







∑ | |1   ∑ | |1    
Segment area is quantified using aperture area variability (AAV). AAV is defined as the 
variation in segment area relative to the maximum aperture area. Segments that similar in area to 
the maximum aperture area contribute to a larger complexity score, i.e. less modulation. The 
AAV is calculated using the leaf position information as follows: ∑ 〈 〉 〈 〉∑ 〈max 〉 〈max 〉  
where A is the number of leaves in the leaf bank.  
Finally, the segment weight is incorporated into the complexity score. Control points with 
a larger number of MUs have a larger weighting and contribute more to the complexity score. 
The weighting is incorporated along with AAV and LSV into the final MCS calculation. The 
MCS for an entire arc, MCSarc, is the product of the LSVcp and AAVcp weighted by the relative 
MU of each control point in the beam. 
 MCSarc is defined as follows:  
2  2   ,  
2.2 Aim 2 
In Aim 2, each treatment plan created in Aim 1 was delivered to the respiratory motion 
phantom. Static and dynamic dose were measured using radiochromic film inside the phantom.  
2.2.1 Ion Chamber Measurements 
Treatment plans were delivered to the respiratory phantom using an Elekta Versa HD 
linear accelerator (Elekta Oncology Systems, Crawley, UK). This accelerator has a 160-leaf 
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MLC supporting up to a 40 x 40 cm2 field size, resulting in a leaf width of 0.5 cm at isocenter. 
This accelerator is used clinically for SBRT procedures at MBPCC. 
 Linear accelerator output was measured before each film measurement session using 
the protocol recommended by Task Group 51 of the American Association of Physicists in 
Medicine (Almond et al., 1999). A Physikalisch-Technische Werkstätten (PTW) GmbH farmer 
ionization chamber, SN: N30006-0074, (PTW, Freiburg, Germany) was placed in a solid water 
phantom (CIRS, Norfolk, VA) and irradiated with 100 MU. The farmer chamber was coupled 
with a CNMC Model 206 dosimetry electrometer, SN: 11207335, (CNMC Company, Nashville, 
TN) in order to measure the charge collected per MU. The output measurements were converted 
to dose and film dose calibration curves (Section 2.2.4) were adjusted accordingly to account for 
changes in daily output.  
 
 Per MBPCC clinical policies, the output was calibrated to a dose of 0.8 cGy/MU for a 
6 MV beam at reference conditions. Reference conditions are at 100 SAD with 10 cm water for a 
Figure 14: Linear accelerator output setup for a 6 MV beam at reference conditions of 100 
SAD at 10 cm depth and 10 cm backscatter of solid water using a 10x10 cm2 field 
size. 
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10x10 cm2 field size, Figure 14. Three readings were taken and the corresponding output was 
calculated using Task Group 51 protocol facilitated by the use of an excel worksheet template in 
use at MBPCC for monthly output calibrators. 
2.2.2 Radiochromic Film Measurements 
 Two-dimensional (2D) dose distributions of each treatment were measured using 
radiochromic film placed inside the cedar insert of the respiratory phantom. Radiochromic film 
was chosen because it is insensitive to ambient light, does not require wet chemical processing 
(i.e. self-developing), and has high spatial accuracy. Insensitivity to ambient lighting greatly 
simplifies the processes of handling, cutting, and loading film. Self-processing film eliminates 
any variations that may arise from wet chemical processing to be eliminated and high spatial 
accuracy is important when measuring dose distributions with steep dose gradients, such as those 
common in SBRT treatment.  
 
 GafChromic EBT3 (International Specialty Products, Wayne, NJ), was the type of 
radiochromic film used to measure the dose distributions. The structure of GafChromic EBT3 
film is shown in Figure 15. This film has been designed with a dynamic dose range of 10-2000 
cGy and has been reported to have minimal photon energy dependence and is nearly tissue 
equivalent (Ashland, 2016).  
 Figure 15: Structure of GafChromic EBT3 Dosimetry Film (Ashland, 2016) 
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A calibration curve was prepared for each batch of film. In this process, two sheets of 
8x10 in2 films were cut into twelve 3x3 in2 pieces and marked for orientation purposes. With one 
film piece unirradiated representing background, eleven pieces of film were exposed to a range 
of doses from 250 to 1425 cGy. Figure 16 shows the cut film pieces for a batch of film and the 
planning doses received.  
Each calibration film was set perpendicular to the radiation delivery in solid water at a 
100 cm SSD and 1.5 cm depth, dmax for 6 MV radiations, with 10 cm of backscatter. Radiation 
was delivered with a 6 MV photon beam using an open 10x10 cm2 field. Per manufacturer 
recommendations, each film was stored for a period greater than 24 hours before scanning to 
ensure that all polymer changes (self-development) had completed. Films were scanned in using 
an Epson Expression 10000XL flatbed scanner (Section 2.3.2) and a calibration curve was 
developed in Radiological Imaging Technology analysis software (Section 2.3.3) using a built in 
calibration procedure.   
Before treatment delivery on the linear accelerator, a piece of radiochromic film was 
prepared by cutting the film flush with the cedar film and tumor insert and punching registration 
Background 250 cGy 500 cGy 
Figure 16: 3x3 in2 pieces of GafChromic EBT3 film with corresponding delivered  dose for 
film’s calibration curve.
750 cGy 900 cGy 
1425 cGy 
1025 cGy 
1350 cGy 1300 cGy 1225 cGy 1175 cGy 1100 cGy 
Background 250 cGy 500 cGy 
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holes in each corner, Figure 17. The registration holes were punched using a hole puncher with 
consistent setting to punch a hole 7/16 and 1/2 inch from longitudinal and lateral edge of the film 
corner, respectively. 
 
 The insert (now containing the film) was placed inside the phantom, which was aligned 
to the room lasers by radiopaque markers placed on the phantom during simulation. A 
kilovoltage cone beam computed tomography (kV-CBCT) scan was taken using the x-ray 
volume imaging (Elekta Versa HD, Elekta Ltd. Crawley, West Sussex, United Kingdom) system 
to align the phantom position with that in the planning CT data set exported from the TPS, 
Figure 18. Each kV-CBCT was acquired with a bow-tie filter (F1) and a small collimator field of 
view with an axial length of 26 cm (S20). Once the kV-CBCT was acquired, it was aligned to the 
reference CT using automatic grey-scale matching. The designated volume for registration 
(clipbox) was defined to encompass the stationary parts of the phantom. Treatment plans were 
then delivered to the phantom, and the resulting dose measured, with and without respiratory 
motion, for a total of 90 deliveries.  
Figure 17: Radiochromic film piece cut flush with cedar film and tumor insert with punched 
registration holes before delivery (left) and after delivery (right).      
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2.3  Aim 3 
 The film from the static and dynamic deliveries in Aim 2 will be compared to the 
Pinnacle3 planar dose distributions in this aim.  
2.3.1 Planar Dose Export 
 The coronal dose plane corresponding to the dose distribution measured by the film 
inside the phantom was exported from the TPS for each treatment plan. Planar doses were 
calculated for a 20x20 cm2 square field. The planar dose tool, Figure 19, was used to create 
ASCII planar dose files at a resolution of 1 mm. The ASCII files were exported, and retrieved 
via file transfer protocol (FTP). 
Figure 18: Screenshot of XVI 3D-kVCBCT registration window. (Green: Acquired CBCT; Purple: 
Pinnacle Export) 
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2.3.2 Digitization of Exposed Films 
Radiochromic film measurements were digitized using an Epson Expression 10000XL 
flatbed photo scanner (Seiko Epson Corporation, Nagano, Japan). This scanner was used to save 
48-bit red-green-blue (RGB) images in tagged image file format (TIFF). Scanner settings are 
shown in Table 3.  
Table 3: Film Scanner Settings  
Parameter Setting
Mode Professional
Document Type Film 
Image Type 48-Bit Color 
Resolution 150 dpi
Target Size Variable 
Image Adjustments Off 
   Figure 19: Screenshot of Pinnacle3 Planar Dose Computation window.  
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 As recommended by the manufacturer, the films were scanned in landscape orientation 
to reduce lateral response artifacts (Ashland, 2015). Care was taken to preserve film orientation 
and time between exposure and processing since both have shown to affect film response 
(Matney, 2008). Additionally, a cutout was designed to make sure that each film was placed in 
relatively the same position on the scanner during readout, as seen in Figure 20. Since the Epson 
scanner has no warm-up process, 10 repeated warm-up scans were performed on the scanner 
before actual image digitization. Each film was digitized at 0.178 mm per pixel in order to 
balance resolution and document size.  
2.3.3 Film Registration  
 Delivered and planned dose distributions were registered and analyzed in Radiological 
Imaging Technology (RIT) v6.3 analysis software (Radiological Imaging Technologies, Inc., 
CO). The Epson scanned 48-bit RGB radiochromic film image was imported as a 16-bit  
 
green channel image since fractionated doses were over 10 Gy (Ashland, 2015). A 2D median 
filter of 5x5 pixels was applied to all imported film to reduce inherent image noise. The 
Figure 20: Epson Expression 10000XL Scanner with radiochromic film inside the cutout to 
ensure all film was scanned in the same relative position. 
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calibration curve, corresponding with the appropriate film batch, was applied to convert each 
film pixel value to dose. The planned planar dose ASCII file was also imported into RIT for 
image registration and analysis. 
 The planar dose image was registered to the film’s measured dose distribution using a 
registration template created within the RIT software. The template was created by acquiring a 
CT scan of the phantom (stationary) with film inside and using the measurement tools in the TPS 
to determine the distances of the film registration holes from isocenter, Figure 21(a). Once the 
registration template was created and applied to the planar dose image, Figure 21(b), the film 
image and planar dose image were registered using a point-based rigid body registration tool. 






Figure 21: GafChromic film with punched holes for film registration (left) and RIT’s image 
registration window (right). 
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2.3.4  Analysis  
Uncertainty Measurements 
The treatment delivery and film analysis processes are subject to error. The quality of 
the results presented herein is directly related to this error. Measurements were performed to 
quantify the uncertainty in these steps.  
The uncertainty in the CBCT software registration algorithm was determined by a 
process similar to that described in Sutton et al., 2014. The phantom was initially aligned to 
isocenter by a kV-CBCT using grey-value registration with only translation shifts. This gave the 
best alignment possible without considering rotations that the couch is unable to account for. 
After the phantom was aligned, 6 repeated measurements were acquired without moving the 
phantom by re-calculating the registration. Ideally, these repeated measurements would have a 
mean and standard deviation of zero, with any deviations from that value indicating the inherent 
noise in the image guidance process.  
The results from the kV-CBCT image guidance measurements are displayed in Table 4. 
The expected mean value is 0.00 mm in all directions, since the phantom was initially aligned 
using a kV-CBCT and the process was repeated without moving the phantom. However, the 
measurements indicate that the kV-CBCT has sub-millimeter accuracy. 
Table 4: Registration results for repeated kVCBCT 
Mean & Standard Error (mm) (N=6) Standard Deviation (mm) (N=6) 
X-Lateral 0.17 ± 0.24 0.59 
Y-Longitudinal -0.50 ± 0.10 0.24 
Z-Longitudinal 0.48 ± 0.21 0.51 
The quality of the film and planar dose registration process was adopted from Vinci, 
2007. The film registration software displays an estimated error value for each film registration 
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point (Δxi, Δyi) by evaluating the geometric relationship between registration points in the planar 
dose and film dose images. These values were taken to directly quantify the quality of the 
registration process, Q, as calculated by: 12 1 ∑ ∆ ∆2 ∆ ∑ ∆ ∆2 ∆  
where N= the number of registration points.  
 The average Q values and spread of Q values from RIT’s film registration are reported in 
Table 5. As a rule of thumb, the standard deviation ( ) should be less than or equal to 1/Pmm, 
where Pmm is the pixel size of the reference image in mm. For the 1 mm pixel size of our 
reference images, the Q value from each registration should be less than 1 mm to be considered 
appropriate. This served as a quality check for all films. 
Table 5: Film Registration Quality (≤1mm) 
Trace Average (mm) (N=30) Range (mm) (N=30) σ (mm) (N=30) 
PS1  0.67 0.35 - 0.96 0.18 
PS2  0.55 0.33 - 0.95 0.16 
Irregular  0.54 0.37 - 0.92 0.17 
ALL 0.60 0.33 - 0.96 0.18 
 
 Additionally, one film was registered 10 times to it corresponding planar dose 
distribution and evaluated. The deviation in quality (Q) from this process (σQ = 0.03 mm) was far 
less than the deviations observed from registering different films. This indicated the error is in 
large part due to film preparation (i.e. the manual cutting of film to fit inside the insert and 
punching of film registration holes). 
 Lastly, one A/P plan was generated and delivered to the phantom three times in one 
session to measure the end-to-end variation in the phantom setup, treatment delivery and film 
analysis. Each film delivery was registered to the corresponding planar dose file in RIT. 
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Longitudinal and lateral profiles were acquired and the displacements between midpoints were 
determined using the 50% isodose line positions. This procedure includes all errors from kV-
CBCT alignment, from treatment delivery, and from film registration and scanning. 










































Figure 22: Longitudinal profiles of three repeated stationary film measurements inside the 
phantom. 




The longitudinal and lateral profiles from the three repeated stationary phantom delivery are 
displayed in Figure 22-23. As measured from the data, the displacements of the midpoint at the 
50% dose level between films are 1.21 mm in the longitudinal direction and 0.17 mm in the 
lateral direction for the film deliveries.  
Analysis Metrics  
 Analysis was performed on all static and dynamic film deliveries using the RIT V6.3 
software package. Once the film and planned dose distributions were registered, five 1-D profile 
measurements along the longitudinal (superior-inferior) and lateral (right-left) axis were acquired 
for each film. One profile through isocenter and four profiles adjacent to isocenter were acquired 
summed and averaged.  
 Target coverage was evaluated using the profile measurements. The analysis metrics 
evaluated the position of the measured dose distributions compared to the calculated 
distributions. The width of the 100% prescription dose, the width of the 95% prescription dose, 
and relative dose and percent dose error at the edges of the GTV, ITV and PTV between planned 
and delivered dose were evaluated. Insufficient target coverage will be considered a relative dose 
below 95% of the prescription in the GTV and a relative dose below 90% of the prescription in 
the PTV. Additionally, the mean, minimum and maximum dose difference for all points inside 
the GTV, ITV, and PTV were calculated between the planned and delivered distributions. Figure 
24 shows longitudinal profiles through both the calculated and measured dose distribution. The 






Additionally, the RIT software has the ability to perform gamma analysis. Gamma 
analysis (Low et al., 1998) was used to compare the agreement between planned and delivered 
distributions with the TPS calculation. Gamma analysis considers the dose difference and spatial 
displacement between each point. RIT’s gamma analysis method (Ju et al., 2008) was performed 
at gamma criteria of 3% dose difference and 3 mm distance to agreement and 5%/3 mm. Gamma 
analysis was performed on the area representing the GTV (sphere), the ITV (MIP) and the PTV 
in the dose distribution. Since the exact positon of isocenter is known on the pinnacle planar dose 
export, it was used to crop a region of interest that fully encompasses these areas. Additionally, 


























Figure 24: Profile plots illustrating the edges and width of the dose distributions at the 95% 
(950 cGy) prescription dose level.
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Chapter 3 
Results and Discussion 
3.1     Plan Complexity 
          In Aim 1, VMAT SBRT treatment plans of varying modulation complexity score values 
were generated. The planning process began by producing very simple treatment plans with only 
planning volumes and dose fall-off objectives. The calculated complexity score for these plans 
resulted in a complexity score of 0.70 and 0.75 for the 1 cm and 2 cm target amplitude, 
respectively. Critical structures were subsequently contoured in the phantom geometry to 
increase complexity and decrease the MCS in increments of 0.05. Successive treatment plans 
were created and the complexity score was steadily decreased until a complexity score of 0.40 
was reached, for a total of 45 treatment plans. The complexity score value of 0.40 was chosen as 
an end point since such values are comparable to those observed in head and neck IMRT 
treatment plans (McNiven et al., 2010).  
3.2     Plan Monitor Units 
            The total number of monitor units was recorded on the basis that the number of monitor 
units has generally been associated with the degree of complexity in a treatment plan (Masi et 
al., 2013; McNiven et al., 2010). Table 6 shows the number of MU in each plan generally 
increases with increasing plan modulation (i.e., decreasing MCS) for all three patients. Figure 25 
depicts the relationship between the number of MU and the MCS for each plan evaluated. The 
graph shows that there is a strong linear correlation (R=0.92) between MCS and number of MU 
in this study. 
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 Table 6: Total Number of monitor units (MU) 
Patient Trace 1 Patient Trace 2 Patient Trace 3 
MCS 1 cm 2 cm 1cm 2 cm 1 cm 2 cm 
.75 -- 1715 MU -- 1719 MU -- 1716 MU 
.70 1765 MU 1792 MU 1705 MU 1803 MU 1775 MU 1776 MU 
.65 1799 MU 1960 MU 1945 MU 1901 MU 1903 MU 1856 MU 
.60 2046 MU 2149 MU 2050 MU 2107 MU 2074 MU 2047 MU 
.55 2538 MU 2352 MU 2285 MU 2320 MU 2287 MU 2384 MU 
.50 2770 MU 2785 MU 2492 MU 2805 MU 2749 MU 2597 MU 
.45 3073 MU 3286 MU 2701 MU 2937 MU 2866 MU 2986 MU 
.40 3129 MU 3711 MU 3149 MU 3057 MU 3154 MU 3092 MU 
3.3 Film Analysis 
          Calculated dose distributions from the TPS were compared with measured static and 
dynamic film dose distributions via profile assessment and gamma analysis. 
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       Figure 25: Plot of MCS and the total number of monitor units for each plan in this study.
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3.3.1 Profile Assessment 
 Longitudinal and lateral profiles of each film measurement were taken. Figures 26-29 
display profile measurements between static, dynamic and calculated dose distributions for 
several cases. The plots also display the isocenter and the extent of the GTV, ITV and PTV at the 
95% prescription level (950 cGy).  
 Figure 26 shows longitudinal profile measurements for a simplified case (MCS=0.70) at 
an amplitude of 2 cm. The static delivery agrees with the planned dose distribution. The effects 
of respiratory motion on the dynamic dose distribution are visble in the edges of the profile. In 
the dynamic profile there is penumbra broadening and loss of coverage in the shoulder regions 
near the PTV. Due to the nature of the respiratory traces, as most patient spend more time in the 
exhale phase, the coverage in the inferior shoulder is less influenced by the respiratory motion 































 Figure 27 shows longitudinal profile measurements for a simplified case (MCS = 0.70) at 
an amplitude of 1 cm. In this plot the static and dynamic profiles agree with the planned dose 
distribution. The dynamic profile at 1 cm shows less penumbra broadening and less coverage 


















































Figure 27: Longitudinal profiles for patient trace #2 at 1 cm amplitude with a plan MCS of 0.70. 





Longitudinal profile measurements for a complex case (MCS=0.40) at an amplitude of 2 
cm are shown in Figure 28. Again, there is penumbra broadening and loss of coverage in the 
shoulder region. Additionally, the profiles show greater dose fluctuations in the target region for 
the more complex case compared to the simplified (MCS=0.70) case.  
Figure 29 shows profile measurements for a complex case (MCS=.40) at an amplitude of 
1 cm. Again, there are dose fluctuations in the target region compared to the simplified case 
(MCS=0.70) and there is a less penumbra broadening compared to the 2 cm amplitude case.   
Lateral profiles were also taken for each film delivery. Due to the design of the insert and 
the dose distribution in the phantom’s geometry only partial lateral profiles could be obtained. 
Figures 30-33 display lateral profiles for simple and complex cases at amplitudes of 1 and 2 cm. 
Note a lateral profile is the perpendicular to the direction of phantom motion and it is seen from 
each measurement that there is relatively no change due to respiratory motion between profiles 
for any given amplitude and complexity. Any error is likely due to the treatment delivery, film 





































































Figure 30: Lateral profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 0.70. 
















































Figure 32: Lateral profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 0.40. 





Since the longitudinal profile corresponds to the direction of phantom motion and 
experiences changes in the dose distribution due to phantom motion, only the longitudinal 
profiles will be evaluated.  
The width of the 100% (1000 cGy) and 95% (950 cGy) prescription dose along the 
longitudinal axis for patient trace 1 are shown in Figures 34-37.  In each measurement it can be 
seen that the width of static dose distribution is wider the planned dose distribution. For the 2 cm 
deliveries, Figures 34 and 35, it can be seen that the dynamic dose distributions have the shortest 
width and that the 95% width fails to meet the required 6 cm to cover the entire PTV as 
prescribed. However, all the 1 cm dynamic deliveries, Figures 36 and 37, meet the required 5 cm 
width to cover the entire PTV. A correlation coefficient of -0.31, 0.03, and -0.06 was calculated 
between the MCS and the dynamic deliveries at 2 cm, 1 cm and all deliveries combined, 






















Figure 34: Width of the 100% prescription dose (1000 cGy) of planned, static and  dynamic 

















































Figure 35: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic dose 
distribution for patient trace 1 at an amplitude of 2 cm. 
Figure 36: Width of the 100% prescription dose (1000 cGy) of planned, static and  dynamic 





 The percent dose error between the planned and delivered dose distributions at the 
longitudinal edges of each delivery can be seen in Tables 7-12. For the dynamic deliveries at 2 
cm, Tables 7, 9 and 11, it can be seen that the percent error at the superior edge (range: -4.06 thru 
-22.43) is generally lower than that for the inferior edge (range: +6.96 thru -14.02). Again, this is 
influenced by the breathing trace as a patient spends more time in the end-of-exhale phase 
corresponding to the inferior edge. This trend is not evident in the dynamic deliveries at 1 cm, 
Tables 8, 10 and 12. The percent dose error at the GTV edge was never less than 2.58% for all 
static and dynamic cases. As you extend out to the ITV and PTV edges the percent dose error 
decreases. This indicates that with sufficient margin the target coverage can be maintained. 
Additionally, the dynamic 2 cm irregular trace, Table 11, has positive values in the inferior 
direction of motion for all cases, whereas the dynamic 2 cm regular traces, Table 7 and 9, has 
negative values in the inferior direction. This is due to the nature of the irregular respiratory 





















Figure 37: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic dose 
distribution for patient trace 1 at an amplitude of 1 cm. 
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Table 7: Percent dose error at GTV, ITV, and PTV edges for patient trace 1 @ 2 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 -0.09 -2.21 -2.22 -1.64 0.61 1.07 -2.27 -1.65 2.60 9.81 -10.96 1.26 
0.70 0.20 -2.14 -1.05 0.72 1.13 -0.94 -2.23 -1.34 2.71 4.52 -12.63 -2.98
0.65 0.13 -0.75 1.64 -0.55 1.11 -0.44 -1.73 -1.02 4.47 5.74 -16.62 0.88 
0.60 0.61 -2.03 1.50 -0.84 2.63 -0.50 -3.99 -3.94 5.29 5.17 -18.02 -0.77
0.55 1.37 -1.13 -2.29 -2.39 3.54 -0.68 -2.52 -5.94 6.22 6.15 -14.44 -4.21
0.50 0.52 -2.63 2.25 -2.58 1.66 -0.88 -7.18 -7.55 6.04 4.52 -22.43 -5.53
0.45 2.36 -2.51 4.54 -0.04 4.75 -1.67 -2.25 -6.04 7.17 4.18 -16.31 -4.76
0.40 2.40 0.36 2.25 -0.64 1.76 -0.31 -10.00 -5.89 4.76 1.52 -21.77 -5.83
 
Table 8: Percent dose error at GTV, ITV, and PTV edges for patient trace 1 @ 1 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 0.35 4.22 0.71 3.72 0.62 0.02 0.52 0.37 3.59 -0.10 1.59 0.15 
0.65 0.53 1.06 -0.60 1.08 0.68 1.08 0.50 1.91 2.73 6.82 1.30 4.17 
0.60 0.90 -0.69 2.15 1.83 2.23 -0.36 1.74 2.07 5.31 4.23 0.36 5.16 
0.55 3.24 -0.13 0.02 0.68 4.40 -0.94 0.02 -0.47 7.97 0.23 -0.59 2.03 
0.50 3.88 0.79 2.93 -0.33 3.41 1.39 2.85 -0.37 6.50 2.53 0.87 -0.40
0.45 3.23 -1.21 2.04 -2.58 4.46 -1.63 4.21 -2.99 6.76 1.73 0.74 -2.58
0.40 4.04 1.53 2.57 1.75 4.06 0.91 2.24 2.98 7.57 1.62 -1.20 0.20 
 
Table 9: Percent dose error at GTV, ITV, and PTV edges for patient trace 2 @ 2 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 2.87 1.54 -0.69 -0.34 2.81 1.06 -2.12 -1.81 3.11 1.15 -10.61 -5.97 
0.70 1.05 -1.07 -1.58 0.66 1.33 -2.27 -3.83 -1.20 2.93 0.03 -13.64 -5.75 
0.65 1.74 1.22 -1.48 -0.83 2.12 1.67 -2.44 -5.05 3.58 2.29 -8.65 -10.09
0.60 1.84 1.01 0.19 -1.09 1.20 1.32 -2.46 -1.93 3.11 1.85 -13.97 -5.75 
0.55 0.04 -1.09 0.56 -0.31 2.51 -0.52 -1.28 -3.58 4.83 3.10 -12.81 -8.59 
0.50 1.00 1.47 0.76 -0.26 3.12 2.75 -5.30 -4.13 7.61 2.98 -19.36 -8.88 
0.45 0.79 -0.21 1.15 -0.33 1.26 -0.76 -0.01 -7.92 7.41 1.27 -19.56 -14.02




Table 10: Percent dose error at GTV, ITV, and PTV edges for patient trace 2 @ 1 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 0.34 -0.37 1.01 -2.24 0.48 -0.68 0.61 -2.05 3.80 1.39 -0.61 -1.42
0.65 2.58 -0.24 0.57 -1.44 5.31 0.54 0.96 -1.52 10.21 0.94 1.69 -2.35
0.60 3.15 0.98 2.07 -0.31 4.36 0.24 2.99 -1.44 13.29 -1.84 4.28 -3.10
0.55 3.41 0.36 1.92 -0.37 6.94 0.09 -0.82 1.01 14.59 5.00 -1.80 6.04 
0.50 2.32 0.54 1.16 -0.39 5.67 0.53 2.09 -1.83 12.42 2.22 4.68 -5.78
0.45 4.07 1.31 2.82 -0.96 6.40 1.85 4.10 -2.03 14.01 1.31 6.63 -0.96
0.40 3.47 -0.02 2.02 0.91 3.29 0.54 1.73 -1.62 10.48 -0.01 7.10 -7.14
 
Table 11: Percent dose error at GTV, ITV, and PTV edges for irregular trace @ 2 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 0.02 1.94 1.07 3.39 2.00 2.41 -0.43 3.15 4.02 3.19 -6.36 5.61
0.70 0.62 2.41 -1.04 2.11 3.78 3.58 -3.13 3.23 7.15 5.40 -15.58 4.93
0.65 -0.34 2.94 -0.05 2.87 3.90 4.30 -0.03 2.52 6.42 6.76 -4.06 3.37
0.60 -0.17 0.86 -0.16 1.80 4.83 1.42 0.51 1.65 8.31 3.79 -6.48 3.27
0.55 -0.83 1.31 0.28 -0.69 3.72 2.53 -3.70 -1.21 1.12 7.28 -16.96 0.05
0.50 -2.56 0.81 -1.23 -0.08 4.32 0.73 -1.62 1.19 8.46 3.41 -12.98 6.96
0.45 -1.88 1.16 4.44 1.19 4.09 1.76 1.55 3.09 6.39 7.33 -6.79 5.06
0.40 -1.54 -1.04 -0.03 1.01 3.84 -0.37 -4.65 -0.28 9.87 5.29 -13.88 4.37
 
Table 12: Percent dose error at GTV, ITV, and PTV edges for irregular trace @ 1 cm  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 -1.04 -0.42 -2.51 1.14 0.52 1.79 -1.24 4.11 1.46 5.40 -0.68 5.47
0.65 0.39 -0.85 -0.54 1.40 3.31 1.91 -0.73 3.71 3.85 4.64 -0.48 6.84
0.60 0.63 0.40 1.01 -0.23 2.12 3.38 1.35 1.90 2.29 6.28 1.07 4.61
0.55 -1.15 -0.84 1.15 -0.49 0.63 1.92 1.33 1.43 1.12 4.86 3.14 4.87
0.50 0.32 -0.48 2.32 -1.01 1.75 0.97 3.71 0.67 2.13 4.35 0.63 4.98
0.45 5.04 0.06 4.35 2.43 8.32 -1.32 4.91 2.78 16.81 4.28 4.90 8.23





 The relative dose at the longitudinal edge of each dose distribution can be seen in Tables 
13-18. Although the dose variations between planned and delivered dose distribution may seem 
substantial, the relative dose at the GTV edges (range: 1137-1366 cGy) and ITV edges (range: 
1054-1263cGy) for the dynamic deliveries were above the prescription at all amplitudes and 
complexity level studied. This means that the GTV and ITV coverage was satisfactorily 
maintained. The relative dose at the PTV edge (range: 934-1131 cGy) for the dynamic deliveries 
at 1 cm, were above 90% of the prescription dose for all plans; where planning constraints 
suggest the PTV should not receive doses below 90%. However, the relative dose at the PTV 
edge (range: 826-1163 cGy) for the dynamic 2 cm deliveries were below 90% of prescription 
dose for several cases.  
 The 2 cm dynamic deliveries show that the relative dose at the superior edge is generally 
lower than the inferior edge. Again, this is influenced by the breathing trace as a patient spends 
more time in the end-of-exhale phase corresponding to the inferior edge. For the 1 cm dynamic 
deliveries, the superior edge of the PTV for the irregular trace of the two most complex plans 
(MCS = 0.45 and 0.40) drop below 95% of the prescription dose, Table 18. This is likely as the 
planned width of the 95% dose distribution for these profiles are exactly the required 5 cm to 
cover the PTV (Appendix D, Figure 148). The 2 cm amplitude dynamic irregular trace, Table 17, 
has the largest relative dose values in the inferior direction and the lowest relative dose values in 
the superior direction compared to all the dynamic traces at an amplitude of 2 cm, Table 13, 15 
and 17. Again, this is due to the nature of the irregular respiratory trace; as the irregular trace 
spends an abnormally large amount of time in the inferior direction and consequently a small 
amount of time in the superior direction. 
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Table 13: Relative dose at GTV, ITV, and PTV edges for patient trace 1 @ 2 cm (cGy)  
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 1183 1160 1157 1160 1113 1087 1082 1057 1055 969 916 894
0.70 1207 1176 1192 1210 1148 1121 1110 1116 1078 1046 917 971
0.65 1200 1195 1218 1198 1159 1147 1126 1141 1101 1066 878 1017
0.60 1222 1202 1233 1217 1191 1171 1114 1131 1116 1074 869 1013
0.55 1229 1222 1185 1207 1208 1172 1137 1110 1146 1088 923 982
0.50 1249 1241 1270 1242 1273 1229 1162 1146 1225 1127 896 1019
0.45 1235 1184 1285 1214 1296 1188 1209 1135 1247 1112 974 1017
0.40 1247 1225 1245 1213 1279 1225 1131 1156 1219 1144 910 1061
 
Table 14: Relative dose at GTV, ITV, and PTV edges for patient trace 1 @ 1 cm (cGy) 
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 1173 1174 1177 1177 1126 1111 1125 1114 1066 1038 1045 1033
0.65 1213 1225 1200 1225 1154 1138 1152 1147 1074 1052 1059 1026
0.60 1199 1216 1214 1247 1165 1135 1159 1163 1095 1029 1044 1038
0.55 1297 1252 1257 1262 1254 1178 1201 1184 1174 1040 1081 1059
0.50 1275 1242 1263 1229 1228 1211 1222 1190 1160 1090 1099 1059
0.45 1269 1204 1255 1188 1266 1190 1263 1174 1198 1114 1130 1067
0.40 1338 1321 1319 1325 1294 1256 1271 1282 1232 1152 1131 1136
 
Table 15: Relative dose at GTV, ITV, and PTV edges for patient trace 2 @ 2 cm (cGy) 
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 1204 1185 1162 1163 1130 1098 1076 1067 1052 993 912 923
0.70 1223 1197 1192 1218 1148 1107 1090 1119 1078 1038 904 978
0.65 1234 1229 1195 1204 1163 1171 1111 1094 1082 1067 954 938
0.60 1237 1238 1217 1213 1176 1184 1133 1146 1091 1083 910 1002
0.55 1213 1214 1219 1223 1208 1180 1163 1144 1138 1117 947 991
0.50 1223 1211 1220 1190 1210 1207 1111 1127 1146 1097 859 971
0.45 1219 1187 1223 1186 1164 1163 1150 1079 1160 1105 869 938
0.40 1261 1238 1254 1250 1222 1178 1214 1142 1196 1111 980 972
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Table 16: Relative dose at GTV, ITV, and PTV edges for patient trace 2 @ 1 cm (cGy) 
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 1130 1147 1137 1126 1069 1101 1071 1086 955 1019 1006 991
0.65 1236 1234 1212 1219 1185 1181 1136 1156 1008 1019 1030 985
0.60 1244 1238 1231 1222 1187 1175 1171 1156 1006 977 1026 964
0.55 1253 1237 1235 1228 1172 1152 1087 1163 993 975 951 985
0.50 1247 1227 1233 1216 1227 1181 1186 1154 1078 1048 1004 966
0.45 1264 1249 1249 1221 1249 1212 1222 1166 1104 1149 1032 1121
0.40 1237 1203 1220 1214 1225 1198 1206 1172 1108 1072 1074 995
 
Table 17: Relative dose at GTV, ITV, and PTV edges for irregular trace @ 2 cm (cGy) 
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.75 1173 1177 1186 1194 1084 1098 1058 1105 998 1009 899 1033
0.70 1206 1209 1187 1205 1129 1146 1054 1142 1048 1070 826 1065
0.65 1209 1226 1212 1225 1139 1176 1096 1156 1032 1106 931 1071
0.60 1218 1210 1218 1222 1165 1168 1117 1171 1060 1098 915 1092
0.55 1222 1223 1236 1199 1164 1198 1081 1154 1062 1151 1083 1072
0.50 1240 1250 1257 1239 1204 1196 1136 1202 1098 1111 881 1149
0.45 1235 1283 1340 1283 1202 1243 1173 1259 1061 1175 930 1150
0.40 1346 1297 1366 1324 1253 1259 1151 1260 1134 1174 889 1163
 
Table 18: Relative dose at GTV, ITV, and PTV edges for irregular trace @ 1 cm (cGy) 
 GTV ITV PTV 
 Static Dynamic Static Dynamic Static Dynamic 
MCS S I S I S I S I S I S I 
0.70 1159 1170 1142 1189 1116 1129 1096 1155 1049 1075 1027 1076
0.65 1183 1187 1172 1214 1154 1150 1109 1171 1076 1080 1031 1103
0.60 1187 1198 1191 1191 1144 1171 1136 1154 1051 1101 1039 1084
0.55 1178 1193 1205 1197 1146 1168 1154 1162 1036 1108 1083 1108
0.50 1224 1161 1248 1155 1200 1147 1223 1144 1102 1109 1086 1116
0.45 1275 1234 1267 1263 1242 1163 1203 1211 1055 995 947 1033




Mean, Minimum and Maximum 
 The mean, minimum and maximum dose errors between the dynamic and planned 
distributions were recorded for the GTV, ITV, and PTV regions for all longitudinal profiles 
measurements. The results for each patient trace at specified amplitude of this analysis can be 
seen in Tables 19-24.  
 The results show that the mean dose difference for the GTV never dropped below 2% at 
any amplitude or complexity level. Also, the minimum dose in the GTV only fell below 5% for 
one case under irregular respirations, Table 23. The minimum dose in the PTV decreases 
considerably for the dynamic deliveries at 2 cm, Table 20, 22, and 24. This is influenced by the 
loss of coverage in the shoulder of the profiles. This was concluded as the magnitude of the 
minimum doses in the PTV does not appear in the GTV or ITV which are subsets of the PTV. 
Additionally, the loss of coverage in PTV shoulder appears to influence the PTV mean dose. 
Table 20 and 22 shows the mean dose is negative for all 2 cm dynamic deliveries for patient 
traces 1 and 2. 
Table 19: Percent dose error in dynamic delivery of patient trace 1 @ 1 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.70 -0.33 -2.24 1.22 -0.44 -2.59 1.22 -0.51 -2.59 1.22 
0.65 -0.81 -1.90 0.77 -0.70 -1.90 1.51 -0.57 -2.35 2.48 
0.60 -0.27 -1.15 2.07 -0.09 -1.44 2.99 0.04 -3.51 4.72 
0.55 -0.10 -1.18 2.50 0.03 -1.18 2.50 0.26 -1.80 6.04 
0.50 -1.13 -3.37 1.16 -0.87 -3.37 2.09 -0.81 -6.15 4.68 
0.45 -0.28 -1.99 2.82 0.00 -2.03 4.01 0.26 -4.99 7.25 





Table 20: Percent dose error in dynamic delivery of patient trace 1 @ 2 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.75 -1.09 -2.22 0.13 -1.59 -3.08 0.13 -1.57 -10.96 1.26 
0.70 -0.23 -1.60 1.94 -0.69 -2.29 1.94 -0.85 -12.63 1.94 
0.65 -0.84 -2.10 1.83 -0.79 -2.10 1.83 -0.80 -16.62 1.83 
0.60 0.17 -1.40 2.46 -0.70 -3.99 2.46 -0.94 -18.02 2.46 
0.55 -0.62 -2.39 1.09 -1.73 -6.17 1.09 -2.11 -14.44 1.09 
0.50 0.49 -2.58 3.89 -0.91 -7.55 3.89 -1.57 -22.43 3.89 
0.45 0.97 -2.17 6.54 0.69 -6.04 6.59 -0.02 -16.31 6.59 
0.40 0.37 -2.52 2.97 -1.05 -10.00 2.97 -1.61 -21.77 2.97 
 
Table 21: Percent dose error in dynamic delivery of patient trace 2 @ 1 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.70 0.05 -1.22 1.12 0.05 -1.22 1.12 0.36 -1.22 3.72 
0.65 -0.31 -0.93 1.39 -0.10 -0.93 1.91 0.21 -0.93 4.17 
0.60 0.57 -1.18 2.87 0.77 -1.18 2.87 1.17 -1.18 5.16 
0.55 -0.43 -1.68 0.68 -0.37 -1.68 0.68 -0.32 -1.68 2.03 
0.50 0.27 -0.89 2.93 0.18 -0.89 3.49 0.55 -1.48 3.49 
0.45 1.15 -2.79 5.87 0.48 -3.30 5.87 0.61 -4.02 5.87 
0.40 0.97 -1.45 4.59 1.15 -1.45 4.59 1.28 -1.45 4.59 
 
Table 22: Percent dose error in dynamic delivery of patient trace 2 @ 2 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.75 -0.56 -1.49 0.51 -0.82 -2.12 0.51 -1.61 -10.61 0.51 
0.70 -0.70 -1.65 0.67 -0.92 -3.83 0.67 -1.81 -13.64 0.67 
0.65 -0.78 -1.48 0.03 -1.37 -5.05 0.03 -2.26 -10.09 0.03 
0.60 -0.63 -1.70 1.04 -0.89 -2.46 1.04 -1.84 -13.97 1.04 
0.55 -0.10 -1.40 1.28 -0.52 -3.58 1.28 -1.61 -12.81 1.28 
0.50 -0.21 -2.85 1.47 -0.77 -5.30 1.47 -2.48 -19.36 1.47 
0.45 -0.87 -2.61 1.15 -0.75 -7.92 3.35 -2.65 -19.56 3.35 
0.40 1.00 -2.09 4.08 0.84 -5.28 4.08 -0.60 -12.78 4.08 
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Table 23: Percent dose error in dynamic delivery of irregular trace @ 1 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.70 -0.12 -2.51 1.62 -0.04 -3.27 4.11 0.35 -3.27 5.52 
0.65 -0.04 -1.61 1.75 0.07 -1.92 3.71 0.55 -1.92 6.83 
0.60 0.04 -1.38 1.52 0.19 -1.38 1.90 0.58 -1.38 4.61 
0.55 -0.10 -0.93 1.51 0.06 -0.93 1.51 0.67 -0.93 4.87 
0.50 0.44 -1.00 2.32 0.59 -1.40 3.77 0.96 -1.40 4.98 
0.45 1.51 -1.28 4.35 2.03 -1.28 4.91 2.54 -1.28 8.23 
0.40 -1.82 -5.05 1.39 -1.10 -5.05 1.78 -0.78 -5.05 2.88 
 
Table 24: Percent dose error in dynamic delivery of irregular trace @ 2 cm  
 GTV ITV PTV 
MCS Mean Min Max Mean Min Max Mean Min Max 
0.75 1.48 -0.04 3.99 1.52 -0.43 3.99 1.37 -6.36 5.61 
0.70 0.10 -1.36 2.78 0.15 -3.13 3.23 -0.29 -15.58 4.93 
0.65 0.44 -0.67 3.19 0.77 -0.84 3.19 0.71 -4.06 3.37 
0.60 -0.47 -2.21 2.96 0.05 -2.21 2.95 -0.01 -6.48 3.27 
0.55 -0.27 -1.39 0.83 -0.48 -3.69 0.83 -1.30 -16.95 0.83 
0.50 -1.60 -4.80 1.52 -1.08 -4.80 1.52 -1.26 -12.98 6.95 
0.45 1.66 -2.95 6.44 1.92 -2.96 6.44 1.71 -6.79 6.44 
0.40 0.29 -1.91 2.64 -0.21 -4.65 2.64 -0.88 -13.87 4.37 
  
Systematic Shift 
 The width of the 100% and 95% prescription dose and the percent dose error and relative 
dose seen at the edges of the static dose distributions are influenced by a systematic shift seen in 
the film data. Looking at the dose profiles for these film measurements, a 1–2 mm shift in the 
longitudinal direction was observed in almost every film analyzed, Figure 38. A similar shift was 
also observed in Mancuso’s, (2011) study. The systematic shift was attributed to uncertainties in 
precisely identifying the isocenter within a 2.5 mm CT slice width. This uncertainty means that 
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there is no guarantee that the isocenter defined in the TPS is at the exact same location as the 















3.3.2 Gamma Analysis   
 Gamma analysis was also used to assess the agreement between planned and delivered 
dose. Figure 39 shows RIT’s gamma analysis results for select cases at 5%/5 mm gamma 
criteria. The software reports the percent of pixels passing the gamma test for the registered dose 
distributions. The red pixels in the images indicate pixels that failed to meet the gamma criteria 











































Figure 38: Longitudinal film profiles displaying a systematic shift between the film (red line) 
and the planed dose data (blue line). 
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 Tables 25-30 show gamma analysis passing rates for a region of interest encompassing 
the GTV for static and dynamic deliveries. The results show that as plan complexity increases 
(i.e. decreasing modulation complexity score) the gamma analysis passing rate decreases. 
Additionally, the results show that the dynamic deliveries generally have lower gamma passing 
rates compared to its corresponding static delivery and commonly the 2 cm dynamic deliveries 




Figure 39: RIT gamma analysis results for patient trace 1 at 1 cm amplitude and MCS of 0.60. (A) 
Static GTV: 92.51% (B) Dynamic GTV: 96.25% (C) Static ITV: 92.53% (D) Dynamic 




















0.70 96.57 % 95.42 % 96.98 % 96.05 %
0.65 99.27 % 98.75 % 99.38 % 98.96 % 
0.60 92.09 % 95.53 % 92.51 % 96.25 % 
0.55 92.47 % 90.55 % 92.72 % 90.95 % 
0.50 90.53 % 83.77 % 91.78 % 84.70 % 
0.45 89.07 % 80.54 % 91.99 % 81.69 % 
0.40 85.54 % 80.12 % 86.37 % 81.17 % 
 














0.75 96.05 % 93.13 % 96.46 % 94.80 %
0.70 98.23 % 90.11 % 98.75 % 91.05 % 
0.65 95.11 % 91.47 % 95.53 % 92.51 % 
0.60 93.03 % 89.18 % 93.55 % 90.32 % 
0.55 95.53 % 88.76 % 96.36 % 89.49 % 
0.50 93.55 % 84.18 % 93.66 % 85.43 % 
0.45 89.28 % 81.79 % 89.70 % 83.36 % 
0.40 87.51 % 85.64 % 88.35 % 86.26 % 
 














0.70 94.90 % 96.88 % 96.15 % 98.75 %
0.65 90.32 % 93.34 % 91.26 % 95.01 % 
0.60 93.86 % 88.97 % 94.17 % 90.74 % 
0.55 89.91 % 90.01 % 91.05 % 91.57 % 
0.50 87.41 % 83.87 % 88.03 % 85.02 % 
0.45 84.29 % 80.85 % 85.33 % 82.10 % 


















0.75 98.54 % 98.34 % 99.27 % 98.44 %
0.70 94.17 % 91.26 % 95.73 % 93.65 % 
0.65 95.21 % 92.09 % 96.15 % 93.76 % 
0.60 95.84 %  90.22 % 96.25 % 92.82 % 
0.55 95.11 % 90.22 % 95.94 % 91.68 % 
0.50 91.47 % 90.53 % 93.03 % 91.57 % 
0.45 89.29 % 81.17 % 90.74 % 83.66 % 
0.40 89.49 % 78.36 % 90.74 % 79.08 % 
 














0.70 97.81 % 90.53 % 98.02 % 90.84 %
0.65 93.44 % 87.41 % 93.55 % 88.03 % 
0.60 90.84 % 91.16 % 91.36 % 91.88 % 
0.55 95.42 % 92.20 % 95.94 % 92.51 % 
0.50 83.56 % 80.96 % 84.50 % 82.02 % 
0.45 85.95 % 81.06 % 86.78 % 82.01 % 
0.40 82.83 % 73.26 % 83.45 % 74.26 % 
 














0.75 94.69 % 80.44 % 95.53 % 81.69 %
0.70 93.86 % 82.78 % 94.69 % 83.25 % 
0.65 91.57 % 88.14 % 93.34 % 89.59 % 
0.60 92.40 % 83.45 % 92.72 % 85.74 % 
0.55 92.09 % 80.65 % 94.07 % 80.96 % 
0.50 89.59 % 82.52 % 91.36 % 83.25 % 
0.45 91.36 % 85.12 % 92.72 % 87.10 % 
0.40 90.43 % 73.26 % 91.68 % 82.00 % 




Discussion and Conclusion 
4.1 Summary of Findings 
 In this study, we performed a comprehensive investigation of VMAT SBRT delivery for 
lung treatment. To achieve this, a respiratory motion phantom was taken through the 
radiotherapy imaging, planning and delivery stages. Interplay effects on dose delivery were 
studied under varying degrees of plan modulation. Comparisons of planned and delivered 
distributions were used to gauge interplay effects on the delivered dose. Additionally, correlation 
between target coverage and the MCS was used to gauge its ability to indicate potentially unsafe 
plans. I hypothesized that the amount of plan modulation will correlate (R > 0.60) with changes 
in target coverage between planned and delivered dose distributions.  
 The results indicated that as plan complexity increases so does the number of MUs seen 
in the treatment plan (R=0.92). This finding is inconsistent with previous work from McNiven et 
al., 2010. In their study the MCS and number of MU was investigated for correlation between 
different treatment sites; in which no correlation was found. Also, their study found limited 
linear correlation (R=0.41) between the number of MU’s and MCS for a variety of lungs plans. 
However, this study is less generalized as each plan was based on the exact same phantom 
geometry.  
 The profile assessment results show that the effects of respiratory motion are most 
evident for larger amplitude deliveries and at the edges of the dose distribution (i.e. the shoulder 
and penumbra). This was anticipated since previous studies have noted that the larger the 
amplitude the more dosimetric deviations from the planned distribution (Court et al., 2010; Kang 
et al., 2010). The dose variation between planned and delivered distribution at the edges were the 
largest for the most complex plans at the larger amplitudes (2 cm); where this variation reached 
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up to 22%. However, the relative dose values indicated that the GTV, ITV and PTV at amplitude 
of 1 cm maintained satisfactory coverage for the dynamic deliveries at all complexity level 
studied. Furthermore, the results showed that the relative dose at the PTV edge for the dynamic 2 
cm deliveries were below 90% of prescription dose for several cases; where planning constraints 
suggest the PTV should not receive doses below 90%. 
 This data was further supported by the mean, minimum and maximum dose deviations 
between planned and delivered profile points. Again, the smallest deviations were seen in the 
GTV. Where the mean dose never dropped below 2% and the minimum dose seen was 5.05% for 
the irregular patient trace at the highest degree of complexity. Again, as you extend out to the 
ITV and PTV the magnitude of the dose variations increase. However the mean, minimum and 
maximum data are influenced by treatment planning system modeling quality. As MLC 
modulation increases, the quality of the TPS model becomes important to get an accurate plan. 
The fluctuations seen are due to limitations in the TPS to model plans with increased modulation. 
This is evident as the dose fluctuations appear in the static and dynamic deliveries. Therefore, the 
minimum and maximum dose may be influenced by the dose fluctuations from TPS modeling 
quality.  
The hypothesis of this work was not supported, as indicated by the correlation values. 
The MCS did not correlate with the width, relative dose at GTV, PTV and ITV edges, mean dose 
deviation, or max dose deviation for all plans. No correlation was considered a correlation 
coefficient of less than 0.3. However, a limited correlation of 0.54 and 0.50 was observed for the 
minimum dose deviations in the ITV and PTV regions, respectively, between plan and delivered 
dose distributions.   
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 As expected, the MCS values correlated with the gamma analysis results for static and 
dynamic deliveries. The results show that as the MCS decreases, the gamma analysis results 
generally decreases. The correlation values were 0.85, 0.87, 0.81, and 0.57 for the mean passing 
rates at 5%/5mm for the static 1 cm, dynamic 1 cm, static 2 cm and dynamic 2 cm cases of the 
GTV, respectively. Additionally, a correlation value of 0.65 was obtained for the mean passing 
rate with all GTV cases considered. This find is consistent with previous work from Masi et al., 
2013. In their study the MCS displayed a positive correlation (R > 0.6) with gamma analysis 
results (2%/2mm) for static VMAT deliveries at 2 Gy. Also, their study showed that as the MCS 
values decreased (more modulation) the gamma analysis results dropped below 90% for EBT2 
film measurements. Again, these results are influenced by MLC positioning error and the limited 
accuracy of MLC modeling in the TPS. 
 In conclusion, due to the nature SBRT, where the maximum dose is recommended to be 
between 110% -140% of the prescription dose, dose in the target region and at the edges of the 
target region never dropped below the prescription dose. Additionally, the larger the respiratory 
amplitude the more dosimetric deviations between planned and delivered distributions are 
expected. Lastly, the MCS correlated well with the GTV gamma passing rates for the separate 
cases and similar correlation, between previous works, was noticed when all target cases were 
considered.  
4.2 Limitations 
 One limitation to this work was the Quasar respiratory motion phantom simulates 1D 
motion in the longitudinal direction. Although respiratory motion is usually larger in the 
longitudinal direction, studies have shown that lung tumors move in all three directions (Zhang 
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et al., 2013). Thus, it would be interesting and useful to see the effect of 3D tumor motion on the 
dose delivery.  
 As the film dosimetry process is complex, the accuracy and reproducibility of the 
measurement procedure could be improved. The quality of the results is directly related to this 
process. This includes cutting of the film pieces to fit the insert, positioning of the film in the 
insert, the phantom ability to accurately reproduce the respiratory traces, etc. Additionally, 
another type of detector besides EBT3 film can potentially be beneficial. The study by Masi et 
al., (2011) showed that EBT film gave the worst gamma analysis results compared to other 
dosimetric systems, see Figure 40. 
 
 RIT image registration procedure estimates the error in the registration process. This 
error can result from the inaccuracy in cutting of film’s registration holes, the determination of 
hole centers and the subpixel registration. Furthermore, it has been noted that an increase in the 
resolution of the planar dose file increases the accuracy of RIT’s gamma analysis results 
(Mancuso, 2011).  
 Another limitation is that no statistical tests were performed on the film data because the 
given sample size lacked sufficient statistical power. Also, this project did not account for 
Figure 40: Comparison of calculated and measured dose distributions for different dosimetric 
systems. Percentage of points passing gamma criteria of 3%/3mm. (Masi et al., 2011) 
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deformation of the tumor. Previous studies have shown that in structures such as lungs, tumor 
and organ deformation can occur (Rosu et al., 2005).   
4.3 Future Work 
 In the future one could expand the number of patient specific respiratory traces to be 
planned, delivered and analyzed, in order to provide a larger sample size for statistical analysis 
of the data.  
 The clinical practice of SBRT is expected to increase in use for other cancers; therefore 
one could also expand the range of treatment sites studied. The results can be very different due 
to the different planning constraints, levels of modulation, target sizes, and motion 
characteristics. For example, the liver is another site that has been widely treated with SBRT and 
has considerable amount of changes in inter-fraction position due to respiratory motion (Fontenot 
et al., 2013).  
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Figure 45: Longitudinal profiles for patient trace #1 at 1 cm amplitude with a plan MCS of 
0.65. 













































Figure 47: Longitudinal profiles for patient trace #1 at 1 cm amplitude with a plan MCS of  
 0.60. 














































Figure 49: Longitudinal profiles for patient trace #1 at 1 cm amplitude with a plan MCS of  
 0.55. 













































Figure 51: Longitudinal profiles for patient trace #1 at 1 cm amplitude with a plan MCS of  
 0.50. 












































Figure 54: Longitudinal profiles for patient trace #1 at 2 cm amplitude with a plan MCS of 
0.40. 




























































































Figure 57: Longitudinal profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 
0.65. 













































Figure 59: Longitudinal profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 
0.60. 













































Figure 61: Longitudinal profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 
0.55. 













































Figure 63: Longitudinal profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 
0.50. 













































Figure 65: Longitudinal profiles for patient trace #2 at 2 cm amplitude with a plan MCS of 
0.45. 













































Figure 67: Longitudinal profiles for irregular patient trace at 2 cm amplitude with a plan  MCS 
of 0.75. 














































Figure 69: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.70. 













































Figure 71: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.65. 













































Figure 73: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.60. 














































Figure 75: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.55. 















































Figure 77: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.50. 













































Figure 79: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.45. 



































Figure 81: Longitudinal profiles for irregular patient trace at 1 cm amplitude with a plan  MCS 
of 0.40. 
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Figure 82: Lateral profiles for patient trace 1 at 2 cm amplitude with a plan MCS of 0.75. 













































Figure 84: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.70. 












































Figure 86: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.65. 












































Figure 88: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.60. 














































Figure 90: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.55. 













































Figure 92: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.50. 














































Figure 94: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.45. 













































Figure 96: Lateral profiles for patient trace 1 at 1 cm amplitude with a plan MCS of 0.40. 












































Figure 98: Lateral profiles for patient trace 2 at 2 cm amplitude with a plan MCS of 0.65. 












































Figure 100: Lateral profiles for patient trace 2 at 2 cm amplitude with a plan MCS of 0.60. 












































Figure 102: Lateral profiles for patient trace 2 at 2 cm amplitude with a plan MCS of 0.55. 













































Figure 104: Lateral profiles for patient trace 2 at 2 cm amplitude with a plan MCS of 0.50. 













































Figure 107: Lateral profiles for patient trace 2 at 1 cm amplitude with a plan MCS of 0.45. 












































Figure 108: Lateral profiles for irregular patient trace at 2 cm amplitude with a plan MCS of 
0.75. 













































Figure 110: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.70. 













































Figure 112: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.65. 













































Figure 114: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.60. 













































Figure 116: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.55. 













































Figure 118: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.50. 















































Figure 121: Lateral profiles for irregular patient trace at 2 cm amplitude with a plan MCS of 
0.40. 



































Figure 122: Lateral profiles for irregular patient trace at 1 cm amplitude with a plan MCS of 
0.40. 
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Figure 123: Percent dose error of dynamic delivery for patient trace 1 at 1 cm 




















































Figure 126: Percent dose error of dynamic delivery for patient trace 1 at 2 cm 






















































Figure 128: Percent dose error of dynamic delivery for patient trace 1 at 2 cm 


















































Figure 129: Percent dose error of dynamic delivery for patient trace 2 at 1 cm 

















































Figure 132: Percent dose error of dynamic delivery for patient trace 2 at 2 cm 
















































Figure 134: Percent dose error of dynamic delivery for patient trace 2 at 2 cm 

















































Figure 136: Percent dose error of dynamic delivery for irregular trace at 1 cm 















































Figure 138: Percent dose error of dynamic delivery for irregular trace at 2 cm 















































Figure 140: Percent dose error of dynamic delivery for irregular trace at 2 cm 
Figure 139: Percent dose error of dynamic delivery for irregular trace at 2 cm 
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Figure 142: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic 
dose distribution for patient trace 2 at an amplitude of 2 cm. 
Figure 141: Width of the 100% prescription dose (1000 cGy) of planned, static and dynamic 















































Figure 144: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic 
dose distribution for patient trace 2 at an amplitude of 1 cm. 
Figure 143: Width of the 100% prescription dose (1000 cGy) of planned, static and dynamic 
















































Figure 145: Width of the 100% prescription dose (1000 cGy) of planned, static and dynamic 
dose distribution for irregular trace at an amplitude of 2 cm. 
Figure 146: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic 

















































Figure 148: Width of the 95% prescription dose (950 cGy) of planned, static and dynamic 
dose distribution for irregular trace at an amplitude of 1 cm. 
Figure 147: Width of the 100% prescription dose (1000 cGy) of planned, static and dynamic 
dose distribution for irregular trace at an amplitude of 1 cm. 
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Appendix E. Gamma Analysis Supplemental Tables 














0.70 91.42 88.04 92.53 88.99
0.65 95.04 94.96 95.28 95.83 
0.60 91.97 84.03 92.53 84.82 
0.55 86.86 91.90 87.49 92.45 
0.50 88.01 85.85 88.49 87.03 
0.45 79.84 85.36 80.28 86.15 
0.40 80.25 80.48 80.65 80.56 
  














0.75 90.26 88.41 90.39 90.65
0.70 90.06 88.28 91.05 89.34 
0.65 86.90 86.37 88.22 87.16 
0.60 85.52 86.04 86.31 87.16 
0.55 84.27 82.36 85.12 83.87 
0.50 82.49 67.15 82.82 67.81 
0.45 81.47 64.32 82.42 65.52 
0.40 87.10 75.64 88.22 76.50 
 














0.70 95.12 97.02 95.62 98.59
0.65 90.16 95.04 90.82 96.28 
0.60 89.66 94.46 90.16 95.45 
0.55 85.13 82.45 86.31 83.87 
0.50 85.53 84.37 85.69 85.03 
0.45 81.80 84.45 82.80 85.36 
0.40 78.33 79.98 79.49 82.38 
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0.75 89.07 98.75 90.65 99.14
0.70 94.67 94.27 96.77 95.19 
0.65 92.50 93.09 93.09 94.34 
0.60 96.58 95.52 97.56 96.58 
0.55 93.22 90.13 94.47 91.05 
0.50 82.23 83.75 83.26 84.46 
0.45 88.02 81.90 89.27 83.21 
0.40 85.25 70.44 85.85 71.63 
 














0.70 93.78 83.40 94.11 83.99
0.65 96.32 84.69 96.79 85.38 
0.60 90.62 79.35 90.98 80.28 
0.55 91.15 85.62 91.88 86.21 
0.50 81.56 73.29 82.14 74.54 
0.45 82.90 78.48 83.21 78.76 
0.40 80.65 75.84 81.91 75.93 
 














0.75 90.01 80.14 90.28 81.65
0.70 88.06 86.37 88.22 87.52 
0.65 87.56 77.90 89.24 80.57 
0.60 87.98 78.52 88.13 79.16 
0.55 86.90 76.12 87.22 78.22 
0.50 81.62 78.51 81.93 79.31 
0.45 85.72 76.89 86.25 78.34 


















0.70 85.94 85.32 86.51 85.84
0.65 92.01 91.49 92.30 92.64 
0.60 90.77 85.99 91.58 86.56 
0.55 87.57 93.74 87.90 93.97 
0.50 83.34 85.41 83.59 86.18 
0.45 78.14 70.83 78.77 71.45 
0.40 85.03 84.07 85.41 84.27 
 














0.75 86.56 83.59 86.90 84.66
0.70 87.23 86.73 87.72 88.05 
0.65 86.19 88.59 86.61 89.29 
0.60 86.03 87.43 86.52 87.97 
0.55 82.22 79.62 83.01 80.53 
0.50 82.55 72.22 83.63 73.05 
0.45 80.32 75.24 81.11 75.86 
0.40 80.12 78.09 80.94 78.68 
 














0.70 95.57 97.96 96.17 98.86
0.65 93.28 94.92 93.68 95.37 
0.60 94.67 96.86 94.92 97.31 
0.55 88.67 86.18 89.24 87.09 
0.50 87.41 90.64 87.51 91.09 
0.45 83.62 90.54 84.02 91.14 


















0.75 91.94 99.17 93.01 99.46
0.70 95.74 94.07 96.94 95.33 
0.65 94.92 94.42 95.29 95.08 
0.60 96.55 96.94 97.27 97.60 
0.55 94.09 95.78 94.87 96.36 
0.50 89.17 84.08 89.83 84.58 
0.45 91.90 85.86 92.39 86.44 
0.40 88.18 81.77 88.51 82.55 
 














0.70 94.26 86.78 94.92 86.99
0.65 91.49 90.63 92.65 91.25 
0.60 88.34 87.18 88.56 87.84 
0.55 85.12 88.51 87.01 88.67 
0.50 86.24 82.34 87.51 82.76 
0.45 83.45 79.24 83.45 80.54 
0.40 79.23 75.63 80.32 78.17 
 














0.75 86.90 89.25 87.20 90.10
0.70 90.15 82.64 90.37 83.01 
0.65 86.23 84.25 86.52 84.71 
0.60 83.78 82.69 84.31 83.36 
0.55 85.30 76.23 85.62 77.77 
0.50 79.29 71.45 82.36 71.83 
0.45 74.81 77.24 75.41 78.56 
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